10x Genomics & Single Cell Sequencing
Former Director at 10x Genomics
inpractise.com/articles/10x-genomics-and-single-cell-sequencing
10x Genomics & Single Cell Sequencing(December 8, 2022)
Former Director at 10x Genomics
The executive has over 22 years experience in biotech and is the Former Director at 10x Genomics, responsible of managing the top pharma customer accounts.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
80 plus.
That's in line. I wish I knew what they were selling it at, but it is impressive they pre-sold 100. I've always believed 10X was operating from a position of strength and playing offense in single cell, but they are playing a different sport with spatial. NanoString beat them to market, so did Vizgen eventually, and Resolve is making noise. This is a crowded, competitive landscape which includes Akoya, so if that instrument is going to be expensive, far less customers will buy multiple platforms. In some ways, it was a race to lock in the heavy hitter customers. I suspect those 100 instruments were offered at deep discounts to ensure their instrument was on the floor and not Vizgen's. That instrument is not currently available so they probably sacrificed margin to get share, otherwise they would miss the boat because the launch is way behind schedule.
This is a snippet of the transcript, sign up to read more.
Related Content
10x Genomics, Azenta & Next-Gen Sequencing
Former Field Scientist at GENEWIZ and Mission Bio
Azenta Life Sciences, Biostorage, & Medical Lab Equipment
Former Director at Brooks Life Science Systems, Azenta
BioLife Solutions: Stirling Ultracold, Cold Storage & Strategic Review
Former President at BioLife Solutions
10x Genomics: Visium, NanoString Tech & Future of Single-Cell Analysis
Former Sales Manager at 10x Genomics
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.